Pharmaceutical Substances Syntheses, Patents, Applications - Part 30 ppt

Bupheniode B 291 Phltbogel (Lipha Sant6)- I: Opino (Bayropharm)- USA: Adrin (Major); wfm comb. comb.; wfm Arlidin (USV); wfm Bupheniode KI'C: C02 Use: antihypertensive, vasodilator RN: 22103-14-6 MF: C,,H2,I,NO2 MW. 551.21 EINECS: 244-781-8 LD,: >600 mgkg (M, i.p.); >2 glkg (M, p.0.) CN: 4-hydro~y-3,5-diiodo-~-[l-[(l-methyl-3-phenylpropyl)amino]ethyl]bcnzcnemethanol buphenine (q. v.) Reference(s): ZA 680 046 (HoudC; appl. 29.12.1967; F-prior. 10.1.1967,21.12.1967). Furmulation(s): amp. 4 mg, 6 mg; tabl. 4 mg, 6 mg Trade Narne(s): F: Proclival (HoudC); wfm Bupivacaine (Marcain) ATC: NOlBBOl Use: local anesthetic RN: 21 80-92-9 MF: CIRHZ8N2O MW. 288.44 EINECS: 21 8-553-3 LD,,: 7100 /.~g/kg (M, i.v.); 5600 @kg (R, i.v.) CN: I-butyl-N-(2~6-dimethylphenyl)-2-piperidinecarboxamide monohydrochloride RN: 18010-40-7 MF: C,,H,,N,O . HCI MW: 324.90 EINECS: 241-917-8 pyridine- 2.6-dirnethyl- 2'.6'-picolino- 2-carbonyl aniline (1) xylidide chloride 292 B Bupranolol 1 -butyl-2-(2,6-dimethyl- onilinocarbonyl)pyridinium bromide (Ill) I Bupivacaine 1 pipecolinoyl piperidine-2-carboxylic chloride ocid (2.6-dimethyl- onilide) Reference(s): DE 1 161 900 (AB Bofors; appl. 19.7.1955; S-prior. 6.4.1955). DE 1 169 941 (AB Bofors; appl. 19.7.1955; S-prior. 28.4.1955). GB 869 978 (AB Bofors; appl. 13.2.1959; S-prior. 13.3.1958). Ekenstarn, B. af et al.: Acta Chem. Scand. (ACHSE7) 11, 1183 (1957) alternative syntheses: US 2 792 399 (AB Bofors; 1957; S-prior. 1954) US 2 955 11 1 (AB Bofors; 1960; appl. 1957). Fornzulation(s): amp. 0.25 %, 0.5 %: inj. flask 0.25 %, 0.5 %, 0.75 % Trade Name(s): D: Bupivacain (RhGne- GB: Poulenc Rorer) Carbostesin (Astra) Dolanaest (Strathmann) I: F: Marcai'ne (Astra) Marcai'ne adrknaline (Astra)-comb. Bupranolol Marcain (Astra) Marcam iperbarlca Marcain with Adrenaline (Pi errel) (Ash-comb. J: Marcain (Yoshlmotl- Bupiforan (Bieffe Medital) Takeda; as hydrochloride) Marcaina (Pierrel) IJSA: Sensocraine (Astra; as Marcaina adrenalina hydrochloride) (Pierrel)-comb. ATC: C07AA19 Use: beta blocking agent RN: 14556-46-8 MF: CI4H,,CINO2 MW: 271.79 LD,,: 45 mgkg (M, i.v.) CN: l-(2-chloro-5-methylphenoxy)-3-[(l,l-dimethylethyl)amino]-2-propanol hy drochlorirle RN: 15148 80-8 MI?: C,4H,,C1N0,.HCl MW: 308.25 EINECS: 239-208-3 LD,,: 39.3 mg/kg (M, i.v.); 329 mglkg (M, p.0.); 15.3 mglkg (R, i.v.); 518 mglkg (R, p.0.); 438 mgkg (dog, p.0.) Buprenorphine B 293 2-chloro-5- epichloro- (2-chloro-5- Bupranolol methylphenol hydrin rnethylphenyl) glycidyl ether Reference(s): DE 1 236 523 (Sanol-Arzneimittel; appl. 15.2.1962). US 3 309 406 (Sanol; 14.3.1967; appl. 24.3.1965). Formulation(s): tabl. 50 mg, 100 mg, 200 mg Trade Name(s): D: Betadrenol (Schwarz) J: Bupranolol Hydrochloride Looser (Kaken; as F: BCtadran (J. Logeais); wfm (Shin Nihon Jitsugyo; as hydrochloride) I: Betadrenol (Schwarz) hydrochloride) Buprenorp hine ATC: N02AEO1 Use: analgesic RN: 52485-79-7 MF: C2,H4,NO4 MW: 467.65 EINECS: 257-950-6 LD,,: 24 mgkg (M, i.v.); 260 mglkg (M, p.0.); 31 mgkg (R, i.v.) CN: [5a,7a(S)]-17-(cyclopropylmethyl)-a-(l,l-dimethylethyl)-4,5-epoxy-18,19-dihydr0-3-hydroxy-6- rnethoxy-a-methyl-6,14-ethenomorphinan-7-methanol hydrochloride RN: 53152-21-9 MF: C2,H4,N04 . HCI MW: 504.1 1 EINECS: 258-396-8 thebaine 7a-acetyl-6,14-endo- ethanotetrohydro- thebaine (I) methyl vinyl ketone tert-butyl- magnesium chloride H,C*O 7a-acetyl-6.14-endo- ethenotetrohydro- thebaine [(IS)-1-hydroxy-1.2.2- trimethylpropyl]- tetrohydrotheboine (11) 294 B Buserelin 1. BrCN. CH2C12 1. Ch , CHZCIZ. N(C2H& 2. KOH, diethylene glycol. 170 OC 0 2. LiAIH4, THF 11 rrr 1. cyclopropone- 1. brornocyan carbonyl chloride CHs 6.14-endo-ethano-7a- [(IS)-1-hydroxy-l,2,2- trirnethylpropylltetro- hydronorthebaine N-cyclopropylrnethyl-6,14- endo-ethono-7u-C(15)- 1 - hydroxy-1 ,2,2-trirnethylpropyl]. tetrahydronortheboine (111) KOH, diethylene glyco1.210-220 OC Buprenorphine i DE 1 620 206 (Reckitt & Colman; appl. 15.6.1966; GB-prior. 15.6.1965). US 3 433 791 (Reckitt & Sons Ltd; 18.3.1969; GB-prior. 15.6.1965). forr~zulation with naloxone: EP 144 243 (Reckitt & Colman; appl. 5.12.1984; GB-prior. 6.12.1983). Fonnulatior~(s): amp. 0.3 mglml; sublingual tabl. 0.4 pg 200 pg (as hydrochloride) Trade Natne(s): D: Temgesic (Roche; 1981) GB: Temgesic (Reckitt & J: Lepetan (Otsuka; 1984) F: Subutex (Schering-Plough) Colman; 1978) USA: Buprenex (Reckitt & Temgesic (Schering- I: Temgcsic (Boehringer Colman; 1985) Plough; 1987) Mannh.) Buserelin ATC: Use: L02AEO1 synthetic nonapeptidc agonist analog of gonadorelin (LH-RH), gonad stimulating principle for treatment ol hormone sensitive prostatic carcinoma and endometriosis RN: 57982-77-1 MF: C60H8,N,60,3 MW: 1239.45 EINECS: 261-061-9 CN: 6-[O-(I ,l-dimethylethyl)-~-serine]-9-(N-ethyl-~-prolinamide)-1O-deglycinamideluteinizing hormone- releasing factor (pig) monoace tate RN: 68630-75-1 MF: ChOHRhN16013. C2H402 MW: 1299.50 LD,,,: 56 mgkg (M, i.v.); >1 glkg (M, p.0.); 36 mgkg (R, i.v.); >400 mglkg (R, p.0.) Buserelin B 295 diacetate RN: 59179-42-9 MF: ChOHIlhNLh013. 2C2H402 MW: 1359.55 NHEt NHEt NHEt NHEt NHEt NHEt NHEt NHEt 3-hydroxy-4-oxo-3,4-dihydro-1.2.3-benzotriozinyl ester 2: benzyloxycorbonyl Bzl: benzyl ether OTcp: 2.4,5-trichlorophenyl ester ONSu: N-hydroxysuccinimidyl ester N3: ozide N2H3: hydrozide Bu': tert-butyl ether I Buserelin Reference(s): DE 2 438 350 (Hoechst; appl. 9.8.1974). US 4 024 248 (Hoechst; 17.5.1977; D-prior. 9.8.1974). alternative synthetic methods: DE 2 905 502 (Hoechst; appl. 14.2.1979). parenteral depot formulations: 1) microcapsules with poly-D-(-)-3-hydroxybutyric acid as carrier: DE 3 428 372 (Hoechst; appl. 1.8.1984). EP 172 422 (Hoechst; appl. 20.7.1985; D-prior. 1.8.1984). EP 262 583 (Hoechst; appl. 24.9.1987; D-prior. 2.10.1986, 13.12.1986). 2) with biodegradable poly(hydronyalkyl)aminodicarb~lic acid derivatives: EP 274 127 (Hoechst; appl. 29.12.1987; D-prior. 3.1.1987). 296 B Buspirone medical use as contraceptive: DOS 2 735 515 (Hoechst; appl. 6.8.1977). EP 764 (Hoechst; appl. 1.8.1978; D-prior. 6.8.1977). Formulation(s): nasal spray 10 mg/lO ml; sol. for s. c. amp. 15 mgl10 g; sol. 5.5 mgl5.5 ml for s. c. inj. with 6.6 mg buserelin acetate on polyglycolide matrix Trade Name(s): D: Profact (Hoechst; 1984) Suprefact (Hoechst HoudC; I: Suprefact (Hoechst Italia) Suprecur (Hoechst) 1986) J: Suprecur (Hoechst Japan) F: Bigonist (Cassenne) GB: Suprecur (Shire) Buspirone ATC: NOSBE01 Use: tranquilizer RN: 36505-84-7 MF: C2,H3,N502 MW: 385.51 EINECS: 253-072-2 LDS,: 136 mglkg (R, i.p.) CN: 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione monohydrochIoride RN: 33386-08-2 MF: C2,H,,N5O2. HCI MW: 421.97 EINECS: 251-489-4 LD,,,: 655 mglkg (M, p.0.); 196 mglkg (R, p.0.); 586 mglkg (dog, p.0.) 13 H\]9 + I-(2-pyrimidy1)- piperozine 4-chloro- butyronitrile + 8-oxospiro[4.5]- Buspirone ominobutyl)piperozine (I) decone-7.9-dione Reference(s): DOS 2 057 845 (Bristol-Myers; appl. 24.1 1.1 970; USA-prior. 24.1 1.1969). US 3 976 776 (Mead Johnson; 24.8.1976; prior. 24.1 1.1969). Wu, Y.H. eta].: J. Med. Chem. (JMCMAR) 15,477 (1972). US 3 907 801 (Mead Johnson; 23.9.1975; prior. 24.1 1.1969). US 3 717 634 (Mead Johnson; 20.2.1973; prior. 24.1 1.1969). Formulation(s): tabl. 5 mg, 10 mg Trade Name(s): D: Bespar (Bristol-Myers; F: Buspar (Bristol-Myers GB: Buspar (Bristol-Myers 1985) Squibb; 1988) Squibb; 1987) Busulfan B 297 I: Axoren (Glaxo Wellcome) Buspimen (Menarini) USA: Buspar (Bristol-Myers Buspar (Bristol It. Sud) Squibb; 1986) Busulfan ATC: LO1 ABOl Use: antineoplastic RN: 55-98-1 MF: C6H,406S2 MW: 246.30 EINECS: 200-250-2 LD,,: 110 mgkg (M, p.0.); 1800 p&g (R, i.v.) CN: 1,4-butanediol dimethanesulfonate Reference(s): GB 700 677 (Wellcome Found.; appl. 1950). US 2 917 432 (Burroughs Wellcome; 15.12.1959; prior. 5.10.1954). 1,4-butanediol methanesulfo- Formulation(s): tabl. 0.5 mg, 2 mg Busulfan Trade Namefs): D: Myleran (Glaxo Wellcome) GB: Myleran (Glaxo Wellcome) J: Mablin (Takeda) F: Misulban (Techni-Pharrna); I: Misulban (Nuovo ISM) USA: Myleran (Glaxo Wellcome) wfm Myleran (Wellcome) nyl chloride - - Butacaine ATC: D04AB Use: local anesthetic RN: 149-16-6 MF: C,uH3uN202 MW: 306.45 EINECS: 205-734-7 CN: 3-(dibuty1amino)-1-propanol4-aminobenzoate (ester) monohydrochloride RN: 5892-15-9 MF: C,,H3,N202 . HCI MW: 342.91 EINECS: 227-568-4 LD5,: 21 mgkg (M, i.v.) sulfate (2:l) RN: 149-15-5 MF: C,,H,,N2OY 1/2H,S04 MW: 710.98 EINECS: 205-733-1 LD,,: 12 mgkg (M, i.v.) 4-nitro- 3-dibutylomino- benzoyl 1 -propon01 chloride 298 B Butalamine Butacaine Referencets): US 1 358 751 (Abbott; 1920; appl. 1920). US 1 676 470 (Abbott; 1928; GB-prior. 1921). preparation of3-dibutylarnino-1-propanol from allylalcohol and dibutylamine: US 2 437 984 (Abbott; 1948; appl. 1945). butacaine-pamoate: DAS 2 401 605 (Rocador; appl. 14.1.1974; E-prior. 18.1.1973). Formulation(s): cps. 50 mg Trade Name(s): F: Relaxoddi (Leurquin)- USA: Butyn Metaphen (Abbott); Butyn Sulfate (Abbott); comb. wfm wfm Butalamine ATC: C04AX23 Use: vasodilator RN: 22131-35-7 MF: C,8H28N40 MW: 316.45 EINECS: 244-794-9 CN: N,N-dibutyl-N-(3-phenyl- 1,2,4-oxadiazol-5-y1)- 1,2-ethanediamine hydrochloride RN: 28875-47-0 MF: C,,H,,N,O . xHC1 MW: unspecified EINECS: 249-279-2 w 1. sodium amide 2. 2-dibutylomina- 5-amino-3-phenyl- ethyl chloride Butalamine 1,2,4-oxodiazale (cf. irnolornine synthesis) Reference(s): DAS 1 445 409 (J.M.D. Aron-Samuel, J.J. Sterne; appl. 6.7.1962; GB-prior. 11.7.1961, 12.6.1962). US 3 338 899 (Aron-Samuel; 29.8.1967; prior. 9.7.1962). Formulation(s): f. c. tabl. 40 mg, 80 mg Trude Name(s): D: Adrevil (Novartis) Surheme (Aron) F: OxadilCne (Leurquin)- I: Surheme (Lipha); wfm comb. Surheme (Spemsa); wfm Butalbital B 299 Butalbital ATC: NOX (Allylbarbituric acid) Use: sedative RN: 77-26-9 MF: C,,H,,N,O, MW: 224.26 EINECS: 201-017-8 LD5,: 160 mg/kg (R, s.c.) CN: 5-(2-methylpropyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione isobutyl diethyl bromide molonate diethyl isabutyl- molanate 5-isobutyl- ally1 barbituric acid (I) bramide Reference(s): Volwiler, E.H.: J. Am. Chem. Soc. (JACSAT) 47,2236 (1925). Formulation(s): f. c. tabl. 300 mg Trade Name(s): D: Aequiton (Siidmedica)- Bupap (FCR) Pacaps (Lunsco) comb. Esgic (Forest)-comb. Phrenilin (Carnrick) Optalidon (Sandoz)-comb. Fioricet (Novartis) Repan (Everett) F: Optalidon (Sandoz)-comb. Fiorinal (Novartis)-comb. Sedapap (Merz) I: Optalidon (Sandoz)-comb. Fiortal wlcodeine (Genera) Tenake (Seatrace) USA: Anolor (Blansett) Medigesic (U.S. Axocet (Savage) Pharmaceutical) Butamirate ATC: R05DB13 Use: antitussive RN: 18109-80-3 MF: CInH2,N0, MW: 307.43 EINECS: 242-005-2 CN: a-ethylbenzeneacetic acid 2-[2-(diethylamino)ethoxy]ethyl ester citrate (1:l) RN: 18 109-8 1-4 MF: C,nH2,N03 . C,H,O, MW: 499.56 EINECS: 242-006-8 LD,,: 47.2 mglkg (M, i.v.); 865 mglkg (M, p.0.); 37.2 mglkg (R, i.v.); 4164 mglkg (R, p.0.) 2-phenyl- 2-(2-diethylamino- Butamirate butyryl chloride ethoxy)ethonoi 300 B Butanilicaine Reference (s): DE 1 151 51 5 (Hommel AG: appl. 9.3.1 960; CH-prior. 12.3.1959). US 3 349 114 (Hommel AG; 24.10.1967; appl. 17.5.1963). Formulation(s): drops 30 mg; syrup 1.772 mg; suppos. 20 mg; syrup 10.65 mg Trade Name(s): D: Pertix-Hommel (Hommel) Sinecod (Zyma) Sinecod (Karlspharma) I: Butiran (Ecobi) Sinecod (Zyma) Butanilicaine ATC: NOlBBO5 Use: local anesthetic RN: 3785-21-5 MF: C13HlyClN20 MW: 254.76 CN: 2-(butylamino)-N-(2-chloro-6-methylphenyl)acetamide monohydrochloride RN: 6027-28-7 MF: C13HlyClN20~ HCl MW: 291.22 EINECS: 227-893-1 LD,,,: 30 mglkg (M, i.v.) phosphate (1:l) RN: 2081-65-4 MF: C13HlyC1N20 . H3P04 MW: 352.76 EINECS: 218-211-3 C I H&-NH, ' CH3 CH, chloroacetyl 2-chloro-6- 2-chloro-N-(2- chloride methylaniline chloro-6-methyl- pheny1)acetarnide Reference(s): DE 939 633 (Hoechst; 1953). DE 1 005 075 (Hoechst; 1952). process variant: DE 1 009 633 (Hoechst; 1953). Formulation(s): amp. 51 mgl1.7 ml; vial 1 % sol. Trade Name(s): Butanilicaine I D: Hostacain (Hoechst); wfm J: Hostacain (Hoechst); wfm Butaperazine ATC: N05AB09 Use: neuroleptic RN: 653-03-2 MF: C2,H3,N30S MW: 409.60 EINECS: 211-493-9 LD,,: 67 mgkg (M, i.v.); 41 3 mglkg (R, p.0.) CN: 1-[10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazin-2-yl]-l-butanone diphosphate RN: 7389-45-9 MF: CZ4H3,N30S . 2H3P04 MW: 605.59 EINECS: 230-972-3 . [5a,7a(S) ]-1 7-( cyclopropylmethyl)-a-(l,l-dimethylethyl )-4 ,5-epoxy-18,19-dihydr 0-3 -hydroxy- 6- rnethoxy-a-methyl-6,14-ethenomorphinan-7-methanol hydrochloride RN: 5315 2-2 1-9 MF: C2,H4,N04 . HCI MW: 504.1 1 EINECS: 25 8-3 9 6-8 thebaine 7a-acetyl-6,14-endo-. chloride CHs 6.14-endo-ethano-7a- [(IS )-1 -hydroxy-l,2, 2- trirnethylpropylltetro- hydronorthebaine N-cyclopropylrnethyl-6,1 4- endo-ethono-7u-C(15 )- 1 - hydroxy-1 ,2,2-trirnethylpropyl] neuroleptic RN: 65 3-0 3-2 MF: C2,H3,N30S MW: 409.60 EINECS: 21 1-4 9 3-9 LD,,: 67 mgkg (M, i.v.); 41 3 mglkg (R, p.0.) CN: 1-[ 1 0-[ 3-( 4-methyl-1-piperazinyl)propyl ]-1 0H-phenothiazin-2-yl]-l-butanone